- Home
- MBIO vs PPBT Comparison
MBIO vs PPBT Comparison
Compare MBIO & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBIO
- PPBT
- Stock Information
- Founded
- MBIO 2015
- PPBT 2010
- Country
- MBIO United States
- PPBT Israel
- Employees
- MBIO N/A
- PPBT N/A
- Industry
- MBIO Biotechnology: Pharmaceutical Preparations
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- MBIO Health Care
- PPBT Health Care
- Exchange
- MBIO Nasdaq
- PPBT Nasdaq
- Market Cap
- MBIO 7.3M
- PPBT 7.1M
- IPO Year
- MBIO N/A
- PPBT N/A
- Fundamental
- Price
- MBIO $1.22
- PPBT $2.70
- Analyst Decision
- MBIO Strong Buy
- PPBT Strong Buy
- Analyst Count
- MBIO 1
- PPBT 1
- Target Price
- MBIO $100.00
- PPBT $33.00
- AVG Volume (30 Days)
- MBIO 1.0M
- PPBT 16.1K
- Earning Date
- MBIO 05-14-2025
- PPBT 05-20-2025
- Dividend Yield
- MBIO N/A
- PPBT N/A
- EPS Growth
- MBIO N/A
- PPBT N/A
- EPS
- MBIO N/A
- PPBT N/A
- Revenue
- MBIO N/A
- PPBT N/A
- Revenue This Year
- MBIO N/A
- PPBT N/A
- Revenue Next Year
- MBIO N/A
- PPBT N/A
- P/E Ratio
- MBIO N/A
- PPBT N/A
- Revenue Growth
- MBIO N/A
- PPBT N/A
- 52 Week Low
- MBIO $1.13
- PPBT $2.00
- 52 Week High
- MBIO $65.00
- PPBT $20.60
- Technical
- Relative Strength Index (RSI)
- MBIO 35.82
- PPBT 50.46
- Support Level
- MBIO $1.13
- PPBT $2.67
- Resistance Level
- MBIO $1.38
- PPBT $2.94
- Average True Range (ATR)
- MBIO 0.12
- PPBT 0.21
- MACD
- MBIO 0.04
- PPBT 0.04
- Stochastic Oscillator
- MBIO 33.33
- PPBT 62.50
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.